# US 2023/0406839 A1 · Bifunctional Compounds And Methods Of Using The Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406839 A1
- Document ID: US20230406839A1
- Status: Published application
- Kind: A1
- Application number: 18/035,904
- Filed: 2021-11-05
- Published: 2023-12-21
- Earliest claimed: 2020-11-09
- Applicants: The General Hospital Corporation
- Inventors: James T. Kurnick; Ian Seymour Dunn; Matthew M. Lawler
- Web page: https://patentgrep.com/patent/US20230406839A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 211/32: by oxygen atoms
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- G01N 33/582: {with fluorescent label}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides bifunctional compounds and methods of labeling a cell having an azide-modified sugar on its surface by contacting the cell with a bifunctional compound.

## Claims

### Claim 1

A compound haying the formula:
wherein:
A is a small molecule ligand that binds to an FKBP binding site;
B is a chemical linker chosen from an alkyl, an alkenyl, an amide, an ester, a thioester, a ketone, an ether, a thioether, a disulfide, an ethylene glycol unit, a cycloalkyl, a benzyl, a heterocyclic, a maleimidyl, a hydrazone, a urethane, an azole, an imine, a haloalkyl, or a carbamate, or any combination thereof; and
C is an azide reactive molecule chosen from a cyclooctyne, a norbornene, an oxanorbornadiene, a phosphine, a dialkyl phosphine, a trialkyl phosphine, a phosphinothiol, a phosphinophenol, a cyclooctene, a tetrazine, a tetrazole, or a quadricyclane.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein the FKI P binding site is the FK506-FKBP binding site.

### Claim 4 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein the FKBP binding site is the mutant (F36V) FKBP binding site.

### Claim 5 (depends on 1, 2)

The compound according to claim 1 or claim 2, wherein the small molecule ligand is

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound according to any one of claims 1 to 5, wherein the chemical linker is an alkyl or an ethylene glycol unit.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein the chemical linker is an alkyl.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein the chemical linker is a C2-C16alkyl.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein the chemical linker is a C4-C12alkyl or a C4-C16alkyl.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein the chemical linker is a C4-C10alkyl.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein the chemical linker is C4alkyl or C10alkyl.

### Claim 12 (depends on 6)

The compound according to claim 6, wherein the chemical linker is an ethylene glycol unit.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein the chemical linker is a polyethylene glycol (PEG).

### Claim 14 (depends on 13)

The compound according to claim 13, wherein the PEG is PEG2 to PEG16.

### Claim 15 (depends on 14)

The compound according to claim 14, wherein the PEG is PEG2, PEG3, or PEG4.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound according to any one of claims 1 to 15, wherein the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 17 (depends on 16)

The compound according to claim 16, wherein the cyclooctyne is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), monofluorinated cyclooctyne, difluorocyclooctyne, dimethoxyazacyclooctyne, dibenzoazacyclooctyne, biarylazacyclooctynone, 2,3,6,7-tetramethoxy-dibenzocyclooctyne, sulfonylated dibenzocyclooctyne, carboxymethylmonobenzocyclooctyne, or pyrrolocyclooctyne.

### Claim 18 (depends on 16)

The compound according to claim 16, wherein the cyclooctene is trans-cyclooctene (TCO).

### Claim 19 (depends on 16)

The compound according to claim 16, wherein the tetrazine is methyltetrazine, diphenyltetrazine, 3,6-di-(2-pyridyl)-s-tetrazine, 3,6-diphenyl-s-tetrazine, 3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine, or N-benzoyl-3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine.

### Claim 20 (depends on 1)

The compound according to claim 1, wherein:
the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site;
the chemical linker is an alkyl or an ethylene glycol unit; and
the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 21 (depends on 1)

The compound according to claim 1, wherein:
the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site;
the chemical linker is a C2-C16alkyl, or a polyethylene glycol which is PEG2 to PEG16; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 22 (depends on 1)

The compound according to claim 1, wherein:
the FKBP binding site is the mutant (F36V) FKBP binding site;
the chemical linker is a C4-C10alkyl or a polyethylene glycol which is PEG2 PEG3, or PEG4; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 23 (depends on 1)

The compound according to claim 1, wherein:
the small molecule ligand is
the chemical linker is C4alkyl, C10alkyl, or PEG3; and
the azide reactive molecule is DBCO or BCN.

### Claim 24 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 25

A method of labeling a cell having an azide-modified sugar on its surface, the method comprising contacting the cell with a compound having the formula:
wherein:
A is a small molecule ligand that binds to an FKBP binding site;
B is a chemical linker chosen from an alkyl, an alkenyl, an amide, an ester, a thioester, a ketone, an ether, a thioether, a disulfide, an ethylene glycol unit; a cycloalkyl, a benzyl, a heterocyclic, a maleimidyl, a hydrazone, a urethane, an azole, an imine, a haloalkyl, or a carbamate, or any combination thereof; and
C is an azide reactive molecule chosen from a cyclooctyne, a norbornene, an oxanorbornadiene, a phosphine, a dialkyl phosphine, a trialkyl phosphine, a phosphinothiol, a phosphinophenol, a cyclooctene, a tetrazine, a tetrazole, or a quadricyclane.

### Claim 26 (depends on 25)

The method according to claim 25, further comprising contacting the cell with the azide-modified sugar prior to contacting the cell with the compound.

### Claim 27 (depends on 25, 26)

The method according to claim 25 or claim 26, wherein the azide-modified sugar is azido-N-acetylmannosamine (AzNAM), azido-N-acetylglucosamine (AzGlcNAc), azido-N-acetylgalactosamine (AGalNAc), or azido-N-acetylneuraminic acid (AzNANA).

### Claim 28 (depends on 27)

The method according to claim 27, wherein the azide-modified sugar is acetylated at 1, 2, 3, or 4 positions.

### Claim 29 (depends on 25, 26, 27, 28)

The method according to any one of claims 25 to 28, wherein the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site,

### Claim 30 (depends on 29)

The method according to claim 29, wherein the FKBP binding site is the FK506-FKBP binding site.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the FKBP binding site is the mutant (F36V) FKBP binding site.

### Claim 32 (depends on 25, 26, 27, 28)

The method according to any one of claims 25 to 28, wherein the small molecule ligand is

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 25 to 32, wherein the chemical linker is an alkyl or an ethylene glycol unit.

### Claim 34 (depends on 33)

The method according to claim 33, Therein the chemical linker is an alkyl.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the alkyl is a C2-C16alkyl.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the alkyl is a C4-C12alkyl or a C4-C16alkyl.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the alkyl is a C4-C10alkyl.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the alkyl is C4alkyl or C10alkyl.

### Claim 39 (depends on 33)

The method according to claim 33, wherein the chemical linker is an ethylene glycol unit.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the ethylene glycol unit is a polyethylene glycol (PEG).

### Claim 41 (depends on 40)

The method according to claim 40, wherein the PEG is PEG2 to PEG16.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the PEG is PEG2, PEG3, or PEG4.

### Claim 43 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 25 to 42, wherein the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 44 (depends on 43)

The method according to claim 43, wherein the cyclooctyne is dibenzocyclooctyne (DBCO), bicyclo[6.1.0]nonyne (BCN), monofluorinated cyclooctyne, difluorocyclooctyne, dimethoxyazacyclooctyne, dibenzoazacyclooctyne, biarylazacyclooctynone, 2,3,6,7-tetramethoxy-dibenzocyclooctyne, sulfonylated dibenzocyclooctyne, carboxymethyl monobenzocyclooctyne, or pyrrolocyclooctyne.

### Claim 45 (depends on 43)

The method according to claim 43, wherein the cyclooctene is trans-cyclooctene (TCO).

### Claim 46 (depends on 43)

The method according to claim 43, wherein the tetrazine is methyltetrazine, diphenyltetrazine, 3,6-di-(2-pyridyl)-s-tetrazine, 3,6-diphenyl-s-tetrazine, 3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine, or N-benzoyl-3-(5-aminopyridin-2-yl)-6-(pyridin-2-yl)-s-tetrazine.

### Claim 47 (depends on 25)

The method according to claim 25, wherein:
the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site;
the chemical linker is an alkyl or an ethylene glycol unit; and
the azide reactive molecule is chosen from a cyclooctyne, a cyclooctene, and a tetrazine.

### Claim 48 (depends on 25)

The method according to claim 25, wherein:
the FKBP binding site is the FK506-FKBP binding site or the mutant (F36V) FKBP binding site;
the chemical linker is a C2-C16alkyl or a polyethylene glycol which is PEG2 to PEG16; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 49 (depends on 25)

The method according to claim 25, wherein:
the FKBP binding site is the mutant (F36V) FKBP binding site;
the chemical linker is a C4-C10alkyl or a polyethylene glycol which is PEG2, PEG3, or PEG4; and
the azide reactive molecule is DBCO, BCN, TCO, or methyltetrazine.

### Claim 50 (depends on 25)

The method according to claim 25, wherein:
the small molecule ligand is
the chemical linker is C4alkyl, C10alkyl, or PEG3; and
the azide reactive molecule is DBCO or BCN.

### Claim 51 (depends on 25)

The method according to claim 25, wherein the compound comprises the formula:

### Claim 52 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method according to any one of claims 25 to 51, further comprising contacting the cell with a complex, wherein the complex comprises an FKBP binding site linked to a polynucleotide, peptide, or small molecule.

### Claim 53 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method according to any one of claims 25 to 51, further comprising contacting the cell with a complex, wherein the complex comprises an FKBP binding site linked to a polynucleotide.
